Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Coherus Oncology Inc’s stock clocked out at $0.73, down -1.59% from its previous closing price of $0.74. In other words, the price has decreased by -$1.59 from its previous closing price. On the day, 1.19 million shares were traded. CHRS stock price reached its highest trading level at $0.7438 during the session, while it also had its lowest trading level at $0.727.
Ratios:
To gain a deeper understanding of CHRS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.03 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 169.56. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 23 ’25 when Wahlstrom Mats sold 99,988 shares for $0.74 per share. The transaction valued at 73,881 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 84781800 and an Enterprise Value of 301872992. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.43. Its current Enterprise Value per Revenue stands at 1.109 whereas that against EBITDA is -3.88.
Stock Price History:
The Beta on a monthly basis for CHRS is 0.87, which has changed by -0.4741007 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -15.37%, while the 200-Day Moving Average is calculated to be -30.28%.
Shares Statistics:
It appears that CHRS traded 1.57M shares on average per day over the past three months and 1322630 shares per day over the past ten days. A total of 115.91M shares are outstanding, with a floating share count of 105.41M. Insiders hold about 9.07% of the company’s shares, while institutions hold 51.07% stake in the company. Shares short for CHRS as of 1749772800 were 31942421 with a Short Ratio of 20.33, compared to 1747267200 on 33116849. Therefore, it implies a Short% of Shares Outstanding of 31942421 and a Short% of Float of 28.65.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Coherus Oncology Inc (CHRS) is presently subject to a detailed evaluation by 4.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.23, with high estimates of -$0.17 and low estimates of -$0.3.
Analysts are recommending an EPS of between -$0.62 and -$1.23 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$0.68, with 4.0 analysts recommending between -$0.21 and -$1.15.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $10.1M. It ranges from a high estimate of $15M to a low estimate of $5M. As of the current estimate, Coherus Oncology Inc’s year-ago sales were $64.98MFor the next quarter, 7 analysts are estimating revenue of $12.7M. There is a high estimate of $17M for the next quarter, whereas the lowest estimate is $5M.
A total of 7 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $87.55M, while the lowest revenue estimate was $41.89M, resulting in an average revenue estimate of $59.57M. In the same quarter a year ago, actual revenue was $266.96MBased on 7 analysts’ estimates, the company’s revenue will be $99.46M in the next fiscal year. The high estimate is $186.71M and the low estimate is $27.75M.
